December 21, 2014
Source: Oncoimmunology. 2014 Dec 21;3(11):e963424. eCollection 2014.
Authors: N. Bloy, J. Pol, F. Aranda, A. Eggermont, I. Cremer, W.H. Fridman, J. Fučíková, J. Galon, E. Tartour, R. Spisek, M.V. Dhodapkar, L. Zitvogel, G. Kroemer, L. Galluzzi
The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re)activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DC-based preparation (sipuleucel-T, also known as Provenge®) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptive immunity, the interest in harnessing them for the development of novel immunotherapeutic anticancer regimens remains high. Here, we summarize recent advances in the preclinical and clinical development of DC-based anticancer therapeutics.
DC, dendritic cell; DC-based vaccination; FDA, Food and Drug Administration; IFN, interferon; MRC1, mannose receptor, C type 1; MUC1, mucin 1; TAA, tumor-associated antigen; TLR, Toll-like receptor; Toll-like receptor agonists; Treg, regulatory T cell; WT1, Wilms tumor 1; antigen cross-presentation; autophagy; iDC, immature DC; immunogenic cell death; mDC, mature DC; pDC, plasmacytoid DC; regulatory T cells